NEW YORK -- Jan 10, Reuters -- Pfizer Inc PFE.N Chief Executive Albert Bourla said on Monday that moving towards a redesigned COVID-19 vaccine that is specifically targeted to combat the Omicron variant of the coronaviruses is the most likely scenario. Bourla said at the J.P. Morgan Healthcare Conference that Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine variant as well as a shot that would include both the previous vaccine and the vaccine targeted at the Omicron variant.
Bourla said the company could start producing the vaccine in March and file for approval for a redesigned vaccine as soon as March.